16d (edited) • General discussion
Reta
FROM CNBC NEWS
Lilly is not standing still.
The company has a pipeline of next-generation obesity drugs that could extend its lead beyond Zepbound and Foundayo, Risinger said. That includes retatrutide, a triple-agonist that targets three gut hormones and has produced greater weight loss than existing obesity drugs in clinical trials. Lilly plans to seek approval for the drug in the first quarter of 2027.
1
6 comments
Reta
powered by
skool.com/peptides-explained-1547
Peptides Explained: science-first peptide education without hype, bro-science, or medical advice. Learn mechanisms, research, risks, and trends.
Suggested communities
Powered by